These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 10744933)
1. Screening women with a family history of breast cancer--results from the British Familial Breast Cancer Group. Macmillan RD Eur J Surg Oncol; 2000 Mar; 26(2):149-52. PubMed ID: 10744933 [TBL] [Abstract][Full Text] [Related]
2. Interval cancers in the Dutch breast cancer screening programme. Fracheboud J; de Koning HJ; Beemsterboer PM; Boer R; Verbeek AL; Hendriks JH; van Ineveld BM; Broeders MJ; de Bruyn AE; van der Maas PJ Br J Cancer; 1999 Nov; 81(5):912-7. PubMed ID: 10555768 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285 [TBL] [Abstract][Full Text] [Related]
4. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project. Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. Møller P; Reis MM; Evans G; Vasen H; Haites N; Anderson E; Steel CM; Apold J; Lalloo F; Maehle L; Preece P; Gregory H; Heimdal K Dis Markers; 1999 Oct; 15(1-3):179-86. PubMed ID: 10595275 [TBL] [Abstract][Full Text] [Related]
6. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group. Lynge E APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674 [TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
8. Results from the UK NHS Breast Screening Programme 2000-05. Bennett RL; Blanks RG; Patnick J; Moss SM J Med Screen; 2007; 14(4):200-4. PubMed ID: 18078565 [TBL] [Abstract][Full Text] [Related]
9. [Nationwide breast cancer screening fully accomplished; results from the implementation phase 1990-1997. National Evaluation Team for Breast Cancer Screening]. Ned Tijdschr Geneeskd; 2000 Jun; 144(23):1124-9. PubMed ID: 10876708 [TBL] [Abstract][Full Text] [Related]
10. The Scottish breast screening programme's experience of monitoring interval cancers. Everington D; Gilbert FJ; Tyack C; Warner J J Med Screen; 1999; 6(1):21-7. PubMed ID: 10321366 [TBL] [Abstract][Full Text] [Related]
11. Opportunistic breast cancer screening in Hong Kong; a revisit of the Kwong Wah Hospital experience. Lui CY; Lam HS; Chan LK; Tam KF; Chan CM; Leung TY; Mak KL Hong Kong Med J; 2007 Apr; 13(2):106-13. PubMed ID: 17406037 [TBL] [Abstract][Full Text] [Related]
12. Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Nixon RM; Pharoah P; Tabar L; Krusemo UB; Duffy SW; Prevost TC; Chen HH Rev Epidemiol Sante Publique; 2000 Aug; 48(4):325-31. PubMed ID: 11011299 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer detection rates, and standardised detection ratios for prevalence screening in the New Zealand breast cancer screening programme. Richardson A; Graham P; Brown T; Smale P; Cox B J Med Screen; 2004; 11(2):65-9. PubMed ID: 15153320 [TBL] [Abstract][Full Text] [Related]
14. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening? Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971 [TBL] [Abstract][Full Text] [Related]
15. Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. McCann J; Treasure P; Duffy S J Med Screen; 2004; 11(3):117-25. PubMed ID: 15333269 [TBL] [Abstract][Full Text] [Related]
16. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group. Moss S; Blanks R J Epidemiol Community Health; 1998 Feb; 52(2):111-5. PubMed ID: 9578858 [TBL] [Abstract][Full Text] [Related]
17. Early rescreen/recall in the UK National Health Service breast screening programme: epidemiological data. Ong GJ; Austoker J; Michell M J Med Screen; 1998; 5(3):146-55. PubMed ID: 9795876 [TBL] [Abstract][Full Text] [Related]
18. MRI screening in a clinic population with a family history of breast cancer. Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801 [TBL] [Abstract][Full Text] [Related]
19. Seventeen-years overview of breast cancer inside and outside screening in Denmark. Domingo L; Jacobsen KK; von Euler-Chelpin M; Vejborg I; Schwartz W; Sala M; Lynge E Acta Oncol; 2013 Jan; 52(1):48-56. PubMed ID: 22943386 [TBL] [Abstract][Full Text] [Related]
20. Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years. Taylor R; Page A; Bampton D; Estoesta J; Rickard M J Med Screen; 2004; 11(4):199-206. PubMed ID: 15563775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]